These results indicate that increasing metabolic rate by FGFR4 antisense drug combined with inhibition of caloric intake by an appetite suppressant could be an effective therapeutic approach for the treatment of obesity. The gene discussed is FGFR4; the disease is obesity due to melanocortin 4 receptor deficiency.